San Diego, CA. - March 6, 2009, AndroScience Corporation (ASCTM), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne. The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9®cream for 12 weeks to evaluate safety and ascertain preliminary efficacy.
AndroScience Corporation (ASC), a San Diego-based biotech company, is developing ASC-J9®as a topical agent for the treatment of acne.
AndroScience has completed a $6.4 million private-equity financing. The
company’s latest round of financing was led by President Life Sciences
Co., Ltd., joined by Eminent Venture Capital and other private
investors.
AndroScience Corporation (ASC), a San Diego based biotech company,
is developing ASC-J9 as a topical agent for the treatment of acne.
March 2007 – A potential treatment using AndroScience’s compound, ASC-J9®, for a neurodegenerative disorder is published in Nature Medicine
February 2007 - AndroScience Corporation begins Clinical Trials in Humans with Acne Vulgaris
San Diego, January 26, 2007 – AndroScience Corporation, a privately held biotech company, has successfully filed an IND for acne indication and will proceed with Human Clinical Trials in the first quarter of 2007.